CORDIS
EU research results

CORDIS

English EN
Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes

Objective

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations rather than on recovery of the unique product of interest. Technically, this is mostly due to the lack of specific capture systems that would allow direct, « positive » separation of the vaccine from its environment.Vaccines know no borders. For developing countries, the pressure on costs is even more acute, and local production is a way to try to reach the 1$ per dose target. In this context, water sustainability is a major issue, as it is a most sensitive ingredient in bioproduction.
DiViNe will tackle theses cost and environmental issues with technological answers. The partners will combine two major Nano/biotechnology innovations to develop an integrated purification platform amenable to the different natures of vaccines : glycoconjugates, protein antigens and enveloped viruses. They will implement Nanofitins (novel affinity capture ligands) and Aquaporin-based membranes (energy-saving nano-biomimetics used in the cleantech industry), for a « positive » purification approach. High yields are expected (data from antibody purification with Nanofitins), at affordable cost of goods and with a sustainable approach of water recycling.
Novartis Vaccines brings to the Consortium a broad range of targets, and identical strategies can be applied for biopharmaceuticals in general. The development custom affinity capture processes as a sustainable platform is therefore economically relevant, in a very large market. Beyond the technical partnership, the project is a first run for the partners to structure the platform as a commercial offer for downstream processing of biologics.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA

Address

Avenida Da Republica Quinto Do Marques
2781 901 Oeiras

Portugal

Activity type

Research Organisations

EU Contribution

€ 1 663 706,25

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

AFFILOGIC

France

EU Contribution

€ 1 146 225

AQUAPORIN AS

Denmark

EU Contribution

€ 519 400

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

Germany

EU Contribution

€ 1 397 000

GENIBET - BIOPHARMACEUTICALS SA

Portugal

EU Contribution

€ 250 250

GLAXOSMITHKLINE VACCINES SRL

Italy

EU Contribution

€ 813 999,25

Project information

Grant agreement ID: 635770

Status

Ongoing project

  • Start date

    1 March 2015

  • End date

    29 February 2020

Funded under:

H2020-EU.2.1.4.

  • Overall budget:

    € 7 632 281,25

  • EU contribution

    € 5 790 580,50

Coordinated by:

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA

Portugal